- Consumer Products
- Latest 11.23
- Currency US$
- Change 0.34
- Percent Change 3.122 %
- Volume 496,126
- Fri Jul 11, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Mar 31, 2014.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Apr 25||$-0.29||Aug 1||$-0.36|
12 months ended Jul 14, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.